Lactobacillus reuteri in the treatment of Helicobacter pylori infection.
Probiotics have proven to be useful in the treatment of a number of gastrointestinal diseases. Probiotics may compete directly with Helicobacter pylori, possibly by interference with adherence or by the production of antimicrobial molecules. Lactobacillus reuteri has been shown to inhibit H. pylori...
| Publicado en: | Internal & Emergency Medicine Vol. 9; no. 6; pp. 649 - 655 |
|---|---|
| Autores principales: | , , , , |
| Formato: | clinical trial research Journal Article |
| Publicado: |
Springer Nature
Sep2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109677066&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 109677066 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 18280447 46A5 jtl: Internal & Emergency Medicine issn: 18280447 maglogo: N pubinfo: dt: Sep2014 vid: 9 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 109677066 NLM24178436 2012706639 10.1007/s11739-013-1013-z NLM24178436 109677066 ppf: 649 ppct: 6 formats: tig: atl: Lactobacillus reuteri in the treatment of Helicobacter pylori infection. aug: au: Dore, Maria Pina Cuccu, Marianna Pes, Gianni Mario Manca, Alessandra Graham, David Yates sug: ab: Probiotics have proven to be useful in the treatment of a number of gastrointestinal diseases. Probiotics may compete directly with Helicobacter pylori, possibly by interference with adherence or by the production of antimicrobial molecules. Lactobacillus reuteri has been shown to inhibit H. pylori in vitro and in vivo, and theoretically may play a role in eradication therapy. The aim of this study was to examine the efficacy of L. reuteri in H. pylori eradication therapy. This was an open label single center study. H. pylori infection was defined as positive gastric histopathology and (13)C-UBT. Intervention consisted of L. reuteri (DSM 17938) 10(8) cfu plus pantoprazole 20 mg twice a day for 8 weeks. Eradication was defined as a negative (13)C-UBT, 4-6 weeks post therapy. Compliance was considered good if at least 90% of the total number of the pills were taken. 21 of 22 subjects completed the study without protocol violation (mean age 52 years; 36% men). L. reuteri plus pantoprazole twice a day cured 13.6% (3/22; 95% CI 2.9-34.9%) of patients with H. pylori infection by ITT analysis and 14.2% (3/21; 95% CI 3.0-36%) by PP analysis. Overall urease activity assessed before and 4-6 weeks post therapy showed a significant reduction with a difference of mean of 38.8 vs. 25.4 by one-tailed test (P = 0.002). In conclusion, L. reuteri may have a potential role in H. pylori eradication therapy if the cure rate can be improved by changes in dose, dosing interval, or duration of therapy. pubtype: Academic Journal doctype: clinical trial research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|